CHAPEL HILL, NC--(Marketwired - Feb 6, 2014) - Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today the appointment of Robert E. Corder, Ph.D. as Vice President of Manufacturing to lead Heat's ongoing manufacturing efforts. Dr. Corder brings to the Company over 20 years of global and U.S. expertise in bioprocess scale up, manufacturing and cGMP production for new vaccine candidates.
Jeff Wolf, Chief Executive Officer of Heat, commented, "Dr. Corder joins our team at an important time for the company as we prepare to ramp up production of our lead product candidate cell lines for late-stage clinical programs of HS-110 for lung cancer and HS-410 for bladder cancer. His track record with major pharmaceutical companies for implementing global quality systems for R&D to support GMP process development and transferring technology to full scale manufacturing is expected to be an integral component to the success of our clinical development and commercialization strategies."
Dr. Corder has led development processes and compliance of new vaccine candidates from bench scale to full-scale production during his 20-year career directing clinical trial material manufacturing at Wyeth and Pfizer. He has effectively led numerous technology transfer initiatives through to manufacturing, including the successful scale up of Prevnar 13® from pilot, to full scale and into a commercial manufacturing facility. Dr. Corder is a graduate of the University of Cincinnati with a Masters and Ph.D. in Microbiology from The Ohio State University and is the author of multiple publications and abstracts.
"I am excited to join Heat Biologics as the Company produces its ImPACT Therapy cell lines to treat lung and bladder cancer," said Dr. Corder. "Successful and efficient cGMP production of HS-110 and HS-410 will bring these much needed innovative therapeutic cancer vaccines one step closer to commercialization."
About Heat Biologics, Inc.
Heat Biologics, Inc. is a clinical-stage biopharmaceutical company focused on developing its novel, "off-the-shelf" ImPACT therapeutic vaccines to combat a wide range of cancers. Our ImPACT Therapy is designed to deliver live, genetically-modified, irradiated human cells which are reprogrammed to "pump out" a broad spectrum of cancer-associated antigens together with a potent immune adjuvant called "gp96" to educate and activate a cancer patient's immune system to recognize and kill cancerous cells. Heat's HS-110 will be entering Phase 2 trials against non-small cell lung cancer and its HS-410 has entered Phase 1/2 clinical trials against bladder cancer. For more information, please visit www.heatbio.com.
Forward Looking Statements
This press release includes forward-looking statements on our current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and include statements regarding the potential for Heat's ImPACT Therapy, the timing and success of the clinical trials and the expected contributions of Dr. Corder. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the ability for Heat's ImPACT Therapy to perform as designed and the ability to successfully integrate the new management member. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.